Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilaprisan in Uterine Fibroids (ASTEROID 5)
NCT03240523Phase 3Terminated
- Sponsor
- Bayer
- Start
- Jul 2017
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of vilaprisan in Uterine Fibroids (UF) (3 arms), sponsored by Bayer. Primary endpoint: Amenorrhea at 3 months. Started Jul 2017; status: terminated.
02
Drugs
vilaprisan
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT03240523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240523.